Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Dr. Reddy's delivered a steady Q1 FY25 with consolidated revenues of INR 7,673 crore, up 14% YoY, driven by strong US generics (up 19% YoY to $463M) and the Sanofi vaccine portfolio in India. EBITDA margin contracted 357 bps YoY to 28.2% due to higher SG&A (28% YoY increase) from investments in new initiatives and freight costs. PAT stood at INR 1,392 crore. Management expects full-year SG&A of 27.5-28% and R&D of 8.5-9% of sales. Key growth drivers include the Nicotinell acquisition (closing early Q4 CY24), Nestlé JV (operational from August 1), and biosimilar pipeline (Denosumab filing next year, Abatacept by end-2026). Risk: US price erosion and Middle East conflict impacting freight costs could pressure margins.
डॉ. रेड्डीज ने वित्त वर्ष 2025 की पहली तिमाही में अच्छा प्रदर्शन किया। कंपनी की कुल आय 7,673 करोड़ रुपये रही, जो पिछले साल से 14% ज्यादा है। इसकी मुख्य वजह अमेरिका में जेनेरिक दवाओं की बिक्री (19% बढ़कर 463 मिलियन डॉलर) और भारत में सनोफी के टीकों का कारोबार रहा। मुनाफा 1,392 करोड़ रुपये रहा। हालांकि, नए निवेश और माल ढुलाई खर्च बढ़ने से कंपनी का परिचालन मुनाफा (EBITDA) घटकर 28.2% रह गया। आगे, कंपनी निकोटिनेल खरीद, नेस्ले के साथ साझेदारी और नई जैविक दवाओं (बायोसिमिलर) पर ध्यान देगी। जोखिम: अमेरिका में दवाओं के दाम गिरना और मिडिल ईस्ट संकट से माल ढुलाई खर्च बढ़ सकता है।
Promises0 met · 1 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
US price erosion in generics
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
North America Generics Revenue
$463M
+19% YoY
Volume-led growth with higher market share in certain products, partially offset by pricing pressure.
India Business Revenue
INR 1,325 crore
+15% YoY
Growth driven by Sanofi vaccine portfolio and new launches; base business grew mid-single digits.
New Product Launches (Global)
32
N/A
Launched 3 in US, 12 in Europe, 17 in emerging markets during Q1.
Net Cash Surplus
$808M
N/A
Strong cash position supports future investments and M&A.
What Changed vs Last Quarter
NEW
Effective tax rate of 24%-25% for FY25
Normal effective tax rate expected to be in the range of 24% to 25% for the fiscal year.
NEW
US generics to grow in single digits for FY25
Management expects North America generics to continue growing in single digits on a year-over-year basis, compensating for price erosion.
UPDATED
SG&A spend to be 27.5%-28% of sales for FY25
Management expects full-year SG&A as a percentage of sales to be in the range of 27.5% to 28%, despite Q1 being higher at 29.6%.
UPDATED
R&D spend to be 8.5%-9% of sales for FY25
R&D investment expected to be in the range of 8.5% to 9% of sales for the full fiscal year.
DROPPED
India business to grow double-digit in FY25
Excluding divestment income, India business is expected to continue double-digit growth, driven by new product launches and partnerships.
DROPPED
Nestlé JV to contribute post-FY27
The joint venture with Nestlé will require initial investment and brand registration; meaningful revenue contribution expected after FY27.
DROPPED
First meaningful biosimilar launch in FY27
Internal biosimilar pipeline expected to yield first product launch in Europe and US in FY27, with profitability thereafter.
NEW RISK
Freight cost impact from Middle East conflict
Increased freight rates due to Red Sea route issues and air shipments added tens of crores to costs.
NEW RISK
SG&A step-up sustainability
SG&A jumped 28% YoY; analyst questioned if one-offs were included. Management attributed to investments and freight, but full-year guidance implies normalization.
NEW RISK
Cash flow moderation from factoring changes
Free cash flow was lower due to reduced factoring in the US; management expects normalization but it introduces volatility.
RISK GONE
Forex volatility in emerging markets
Emerging market growth in constant currency may be offset by unfavorable forex movements, particularly in Russia and other markets.
RISK GONE
Biosimilar Rituximab CRL delays
US FDA issued a complete response letter for biosimilar Rituximab due to CMC questions; resolution expected around September, but timeline for approval remains uncertain.
RISK GONE
Competition in Revlimid generic
Multiple new entrants in the generic Revlimid market could impact pricing and volume, though management declined to discuss specifics.
🤫 Topics management stopped discussing
Mentioned in Q2 FY24, Q3 FY24, Q4 FY24
Excluding divestment income, India business is expected to continue double-digit growth, driven by new product launches and partnerships.
Fast read
Guidance and risk preview
Management expects full-year SG&A as a percentage of sales to be in the range of 27.5% to 28%, despite Q1 being higher at 29.6%.
Pricing pressure in some key products partially offset volume gains in North America.
View Risks →